Earnings ·
On August 4, 2026, Rhythm Pharmaceuticals reported second quarter 2026 financial results and business updates
RYTMRhythm Pharmaceuticals, Inc.
On August 4, 2026, Rhythm Pharmaceuticals reported second quarter 2026 financial results and business updates. Net product revenue from global sales of IMCIVREE reached $71.3 million, a 19% sequential increase driven by U.S. sales of $51.0 million following the March FDA approval for acquired hypothalamic obesity (HO). The company received more than 400 patient start forms from approximately 300 prescribers since approval. Rhythm reported a net loss attributable to common stockholders of $(50.4) million, or $(0.73) per share, compared to $(48.0) million in the prior year period. Cash and short-term investments stood at $330.9 million as of June 30, 2026. The company also announced preliminary Phase 2 data for investigational drug RM-718 in acquired HO patients, showing an 11.6% mean BMI reduction at 16 weeks with a favorable safety profile regarding hyperpigmentation. Rhythm operates as a commercial-stage biopharmaceutical company focused on treating rare neuroendocrine diseases.